🩺 A 12-Lead ECG in Your Pocket? Inside HeartBeam's ($BEAT) Approval

Описание: This Stockteller episode provides a strategic overview of HeartBeam, Inc. ($BEAT). We cover their massive regulatory victory, receiving FDA 510(k) clearance in December 2025 for their cable-free, 12-lead ECG synthesis software after a successful appeal.

This episode touches on:

The technology behind their credit-card-sized device that provides clinical-grade ECGs at home.
The dramatic turnaround from FDA rejection to clearance.
The company's plan for a limited commercial launch in early 2026.

Would you trust a credit-card-sized device to diagnose your heart?

Like the 'tales' we tell? Support the channel with a coffee! It's never expected, but always appreciated. ☕ Ko-fi: https://ko-fi.com/stockteller

⚠️ Important Disclaimer: HeartBeam ($BEAT) is a nano-cap company with a market capitalization under $30 million. The stock is extremely volatile, as evidenced by its recent 90%+ single-day surge. While FDA clearance is a major milestone, the company still faces significant execution risks related to commercialization, adoption by physicians, and future fundraising. This video is for educational and informational purposes ONLY and is NOT financial advice.

#HeartBeam #BEAT #MedTech #FDA #ECG #CardiacCare #DigitalHealth #NanoCap #PennyStocks #Investing